44 -11 (85) 2025 - F.Sh. Mekhmanov, Sh.A. Naimova - PROGNOSTIC VALUE OF HEMOSTASIS MARKERS IN CORONARY ARTERY RESTENOSIS

PROGNOSTIC VALUE OF HEMOSTASIS MARKERS IN CORONARY ARTERY RESTENOSIS

F.Sh. Mekhmanov - Bukhara State Medical Institute named after Abu Ali ibn Sina

Sh.A. Naimova - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

In patients with ischemic heart disease who undergo percutaneous coronary intervention (PCI), the risk of coronary artery restenosis remains high. This study included 103 patients (48 males, 55 females) aged 18–74 years who were treated at the Bukhara Regional Multidisciplinary Medical Center between 2021 and 2024. A control group consisted of 30 healthy volunteers. Clinical assessment, biochemical evaluation (lipid profile), hemostatic markers (D-dimer, fibrinogen, platelet count, APTT, PT, INR), ELISA (VEGF), and instrumental examinations (ECG, Echocardiography, Ultrasound) were performed. The results revealed a significant association between alterations in hemostasis markers and the development of restenosis. These findings highlight the importance of early risk assessment and provide rationale for personalized antiplatelet/anticoagulant therapy optimization after PCI.

Keywords: ischemic heart disease, coronary intervention, restenosis, hemostasis system, D-dimer, fibrinogen, prognostic index.

First page

245

Last page

249

For citation:F.Sh. Mekhmanov, Sh.A. Naimova - PROGNOSTIC VALUE OF HEMOSTASIS MARKERS IN CORONARY ARTERY RESTENOSIS//New Day in Medicine 11(85)2025 245-249 https://newdayworldmedicine.com/en/new_day_medicine/11-85-2025

List of References

  1. World Health Organization. Cardiovascular Diseases (CVDs) Fact Sheet. Geneva: WHO; 2024.
  2. Neumann F.J., Sousa-Uva M., Ahlsson A. et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. // Eur Heart J. 2019;40(2):87–165.
  3. Alfonso F., Byrne R.A., Rivero F., Kastrati A. Current treatment of in-stent restenosis. // J Am Coll Cardiol. 2014;63(24):2659–2673.
  4. Kastrati A., Schömig A., Elezi S. et al. Predictive factors of restenosis after coronary stent placement. // J Am Coll Cardiol. 1997;30(6):1428–1436.
  5. Undas A., Ariëns R.A.S. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. // Arterioscler Thromb Vasc Biol. 2011;31(12):e88–e99.
  6. Gorog D.A., Fuster V. Platelet function tests in ischemic heart disease: use, interpretation, and future directions. // J Am Coll Cardiol. 2013;61(21):2115–2135.
  7. Becattini C., Agnelli G., Lignani A., et al. D-dimer and risk of cardiovascular disease in patients with coronary artery disease: systematic review and meta-analysis. // Eur Heart J. 2012;33(21):2669–2678.
  8. Siller-Matula J.M., Trenk D., Schrör K. et al. Response variability to P2Y12 receptor inhibitors: expectations and reality. // JACC Cardiovasc Interv. 2013;6(11):1111–1128.
  9. Bai Y., et al. “D-Dimer to Fibrinogen Ratio as a Novel Prognostic Marker in Patients After Undergoing Percutaneous Coronary Intervention: A Retrospective Cohort Study.” [Journal name], 2020. PMC
  10. Galli L., et al. “Platelets, Biomarkers of Coagulation and Fibrinolysis: Preprocedural Platelet Counts and Fibrinogen Plasma Levels Can Identify Patients at Elevated Risk of Early Stent Thrombosis.” Journal of Clinical Medicine, 2024. MDPI
  11. Soomro AY. “The current role and future prospects of D-dimer biomarker.” EHJ Cardiovasc Pharmacother, 2016. OUP Academic
  12. Prisco D., et al. “Postprocedural PAI-1 activity is a risk marker of subsequent coronary restenosis.” J Thromb Haemost, 2001. PubMed
  13. Ünlü Y., et al. “Comparison of levels of inflammatory markers and fibrinogen, D-dimer, PT, CRP, SAA relative to ankle artery disease.” Atherosclerosis, 2006. ScienceDirect
  14. Liu J., et al. “Clinical analysis of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) as a prognostic biomarker for in-stent restenosis.” Medical Science Monitor, 2018.

    file

    download